We responded fast to the COVID-19 pandemic and are proud to have provided the first CE-marked SARS-CoV-2 testing kit. We are a trusted provider of tests to non-governmental organisations.
Our range of end-to-end solutions for COVID-19 testing have supported efforts against the COVID-19 pandemic through molecular, antigen and antibody testing.
- Our PROmate® range of direct-to-PCR assays include the PROmate COVID-19 2G test; the first direct-to-PCR product to be added to the CTDA register of approved products in the UK, designed to detect two SARS-CoV-2 targets within ORF1ab in response to an increasing shift from single-gene to multi-gene testing solutions
- The genesig® series of PCR assays includes 2G and 3G tests as well as our winter diseases panel, a multiplex assay allowing clinicians to sensitively distinguish SARS-CoV-2 from other common winter viruses, such as influenza and respiratory syncytial virus (RSV), in a single test
- Our SNPsig range of SARS-CoV-2 variant identification kits includes EscapePLEX™, a qPCR test for the detection and differentiation of SARS-CoV-2 variants Delta, Delta with K417N and Omicron
- PathFlow® antibody tests represent the serological detection of SARS-CoV-2 IgG antibodies and PathFlow® antigen tests enable rapid detection of the presence of SARS-CoV-2
Backed by world-class bioinformatics surveillance
- Market-leading intelligence is the catalyst behind Novacyt’s ability to respond to and anticipate emerging new SARS-CoV-2 variants
- Global tracking of virus mutations enables us to quickly develop tests that identify variants of concern in less than two hours with our SNPsig range of SARS-CoV-2 variant identification kits
- Novacyt’s bioinformatics surveillance group has worked with a global network of virologists tracking variants to identify the mutations expected to pose the greatest challenges to healthcare and vaccine efficacy